Berberine has been accumulating research for its beneficial impact on metabolic syndrome, insulin sensitivity, and insulin secretion.
In this randomized, double-blind, placebo-controlled clinical trial on 24 patients with a diagnosis of metabolic syndrome, berberine was studied for its effect on waist size and other metabolic measures. 12 patients received 500 mg of berberine three times daily before meals for 3 months. The remaining 12 patients received a placebo.
By the end of the study, 36% of the patients no longer had metabolic syndrome and there was a significant decrease in waist circumference in females. There was also a reduction in systolic blood pressure, triglycerides, glucose, and insulin.
According to the authors of the study:
“Administration of berberine leads to remission of metabolic syndrome and decreases in waist circumference, SBP, triglycerides, and total insulin secretion, with an increase in insulin sensitivity.”